• Molecular NamePamidronate
  • SynonymAcide pamidronique [INN-French]; Acido pamidronico [INN-Spanish]; Acidum pamidronicum [INN-Latin]; APD; Pamidronate Disodium; Pamidronic acid
  • Weight235.069
  • Drugbank_IDDB00377
  • ACS_NO40391-99-9
  • Show 3D model
  • LogP (experiment)-3.048
  • LogP (predicted, AB/LogP v2.0)-5.89
  • pkaN/A
  • LogD (pH=7, predicted)-10.0
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)0.63
  • LogSw (predicted, AB/LogsW2.0)2264.24
  • Sw (mg/ml) (predicted, ACD/Labs)388.53
  • No.of HBond Donors7
  • No.of HBond Acceptors8
  • No.of Rotatable Bonds4
  • TPSA180.93
  • StatusFDA approved
  • AdministrationIntravenous
  • PharmacologyA nitrogen containing bisphosphonate, used to prevent osteoporosis.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability1.0
  • Protein binding54.0
  • Volume of distribution (VD)0.5~0.6 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmPamidronate is not metabolized and is exclusively eliminated by renal excretion
  • Half life28 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySide effects include an allergic reaction, kidney problems, seizures, low levels of calcium, magnesium, or phosphorus in the blood
  • LD50 (rat)N/A
  • LD50 (mouse)N/A